Azenta, Inc.
NASDAQ:AZTA · NASDAQ Global Select
-$0.03 today
Vol 1.07M · Avg 1.16M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:AZTA · Revenue to Net Income
Key Ratios
Analysis
$596.6M of revenue converted into -$178.2M of net income for the selected period. Gross margin is 44.5% and net margin is -31.5%, showing how much revenue survives after costs and taxes. EPS is $-3.96, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $593.8M +3.6% | $573.4M -13.8% | $665.1M +19.7% | $555.5M +8.1% | $513.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $323.5M +1.5% | $318.8M -26.2% | $431.8M +32.9% | $324.9M +8.6% | $299.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $270.3M +6.1% | $254.6M +9.2% | $233.3M +1.1% | $230.6M +7.5% | $214.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 45.5% +1.1pp | 44.4% +9.3pp | 35.1% -6.4pp | 41.5% -0.2pp | 41.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $30.4M -3.6% | $31.5M -7.2% | $34.0M +23.3% | $27.5M +22.9% | $22.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $251.2M -0.8% | $253.1M -10.1% | $281.5M +24.0% | $227.1M +20.5% | $188.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $281.5M -1.1% | $284.6M -9.8% | $315.5M +23.9% | $254.6M +20.7% | $210.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $61.2M -32.5% | $90.7M +6.0% | $85.6M +59.4% | $53.7M -5.6% | $56.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $54.1M -24.5% | $71.6M +29.9% | $55.2M +14.1% | $48.4M +386.5% | $9.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 9.1% -3.4pp | 12.5% +4.2pp | 8.3% -0.4pp | 8.7% +6.8pp | 1.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$11.3M +62.4% | -$30.0M +63.5% | -$82.2M -242.2% | -$24.0M -768.0% | $3.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1.9% +3.3pp | -5.2% +7.1pp | -12.4% -8.0pp | -4.3% -5.0pp | 0.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $18.8M -43.4% | $33.2M -24.1% | $43.7M +115.6% | $20.3M +3109.8% | $632.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 -100.0% | $4.6M +125.3% | $2.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.1M -62.0% | $10.9M -79.0% | $51.8M +267.5% | $14.1M +126.8% | -$52.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$7.1M +62.7% | -$19.1M +37.2% | -$30.4M -206.3% | -$9.9M +79.7% | -$49.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1.2% +2.1pp | -3.3% +1.2pp | -4.6% -2.8pp | -1.8% +7.7pp | -9.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$31.6M -703.0% | $5.2M +129.9% | -$17.6M -1400.0% | $1.4M +106.7% | -$20.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$55.8M +66.2% | -$164.9M -1056.6% | -$14.3M +96.7% | -$429.0M -487.3% | $110.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -9.4% +19.4pp | -28.8% -26.6pp | -2.1% +75.1pp | -77.2% -98.8pp | 21.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +60.5% | -$3 -1304.5% | -$0 -46.7% | -$0 +61.5% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +60.5% | -$3 -1304.5% | -$0 -46.7% | -$0 +61.5% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $45.7M -14.0% | $53.2M -19.7% | $66.3M -11.5% | $74.9M +0.9% | $74.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $45.9M -13.7% | $53.2M -19.7% | $66.3M -11.5% | $74.9M +0.6% | $74.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.28B
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.51B
Neogen Corporation
NASDAQ:NEOG
$1.97B
NovoCure Limited
NASDAQ:NVCR
$1.70B
STAAR Surgical Company
NASDAQ:STAA
$1.43B
Teladoc Health, Inc.
NYSE:TDOC
$1.40B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.27B
Schrödinger, Inc.
NASDAQ:SDGR
$1.16B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.11B
Evotec SE
NASDAQ:EVO
$923.49M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AZTA generate?
Azenta, Inc. (AZTA) reported $593.82M of revenue in fiscal 2025.
Is AZTA profitable?
Azenta, Inc. (AZTA) reported -$55,763,000.00 of net income, with a net margin of -9.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.